Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $96.3 million.

  • Gyre Therapeutics' Shares Outstanding (Weighted Average) rose 3.09% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2023 it was $2.5 million, marking a year-over-year increase of 20.64%. This contributed to the annual value of $93.5 million for FY2024, which is 3593.76% up from last year.
  • Per Gyre Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $96.3 million for Q3 2025, which was up 2.73% from $93.8 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $96.3 million in Q3 2025 and a low of $2.1 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $59.2 million, with a median of $85.5 million in 2024.
  • Data for Gyre Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 3,593.76% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Shares Outstanding (Weighted Average) stood at $2.1 million in 2021, then climbed by 0.26% to $2.1 million in 2022, then increased by 20.60% to $2.5 million in 2023, then spiked by 3,593.76% to $93.5 million in 2024, then rose by 3.09% to $96.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $96.3 million in Q3 2025, compared to $93.8 million in Q2 2025 and $93.6 million in Q1 2025.